Annual Statement of Changes in Beneficial Ownership (5)
31 Janeiro 2022 - 3:59PM
Edgar (US Regulatory)
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
[ ]
Form 3 Holdings Reported
[ ]
Form 4 Transactions Reported
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
ANNUAL STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0362
Estimated average burden hours per response...
1.0
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
Emerald Health Sciences Inc. | 2. Issuer Name and Ticker or Trading SymbolSkye Bioscience, Inc. [SKYE] |
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director __X__ 10% Owner _____ Officer (give title below) _____ Other (specify below)
|
(Last)
(First)
(Middle)
OFFICE 8262, THE LANDING, 200-375 WATER ST. | 3. Statement for Issuer's Fiscal Year Ended (MM/DD/YYYY) 12/31/2021 |
(Street)
VANCOUVER, A1 V6B 0M9
(City)
(State)
(Zip)
| 4. If Amendment, Date Original Filed(MM/DD/YYYY) | 6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form Filed by One Reporting Person
___ Form Filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
|
1.Title of Security (Instr. 3) | 2. Trans. Date | 2A. Deemed Execution Date, if any | 3. Trans. Code (Instr. 8) | 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) |
Amount | (A) or (D) | Price |
Common Stock | 8/7/2020 | | S (1) | 2566666 | D | $0.10 | 111387251 | D | |
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Trans. Date | 3A. Deemed Execution Date, if any | 4. Trans. Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date (MM/DD/YYYY) | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of Derivative Securities Beneficially Owned at End of Issuer's Fiscal Year (Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
(A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
Warrants with Credit Facility of Oct 5, 2018 | $0.50 | 11/1/2018 | | A (1) | 2500000 | | 11/1/2018 | 11/1/2023 | Common Stock | 2500000 | $0 | 2500000 | D | |
Warrants with Credit Facility of Oct 5, 2018 | $0.50 | 2/1/2019 | | A (1) | 2500000 | | 2/1/2019 | 2/1/2024 | Common Stock | 2500000 | $0 | 2500000 | D | |
Warrants with Credit Facility of Oct 5, 2018 | $0.50 | 3/29/2019 | | A (1) | 2500000 | | 3/29/2019 | 3/29/2024 | Common Stock | 2500000 | $0 | 2500000 | D | |
Multi Draw Credit Facility - T2 | $0.40 | 2/1/2019 | | A (1) | 38822 | | 10/5/2022 | 10/5/2022 (2) | Common Stock | 38822 | $0 | 38822 | D | |
Multi Draw Credit Facility - T3 | $0.40 | 3/29/2019 | | A (1) | 5354861 | | 10/5/2022 | 10/5/2022 (2) | Common Stock | 5354861 | $0 | 5354861 | D | |
Explanation of Responses: |
(1) | Transactions were previously reported on various prior Form 4 filings; however, the entries were erroneously reported as non-derivative transactions in Common Stock and the resulting reported total ownership included the misclassified securities. The entry of these transactions is to correct this error and reflect the actual securities held by the Reporting Person. |
(2) | The Multi Draw Credit Facility tranches have the option to convert into Common Stock upon maturity of the facilities. |
Reporting Owners
|
Reporting Owner Name / Address | Relationships |
Director | 10% Owner | Officer | Other |
Emerald Health Sciences Inc. OFFICE 8262 THE LANDING, 200-375 WATER ST. VANCOUVER, A1 V6B 0M9 |
| X |
|
|
Signatures
|
/s/ Stephen Hall | | 1/31/2022 |
**Signature of Reporting Person | Date |
Skye Bioscience (QB) (USOTC:SKYE)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Skye Bioscience (QB) (USOTC:SKYE)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024